Literature DB >> 29988888

Compliance to topical anti-glaucoma medications among patients at a tertiary hospital in North India.

Ketaki Rajurkar1, Suneeta Dubey1, Parmatma Prasad Gupta1, Denny John2,3, Lokesh Chauhan1.   

Abstract

PURPOSE: The present study aims to estimate the prevalence of non-compliance and improper drop administration technique among glaucoma patients and describe common obstacles to medication compliance.
METHODS: A hospital-based cross-sectional study, using standardized questionnaire and direct observation by study personnel was conducted among glaucoma patients aged 18 years and above at a tertiary care charitable eye hospital in North India. 151 consecutive glaucoma patients on medical therapy following up at the glaucoma clinics for at least 6 months were recruited. Non-compliance was defined as missing at-least one drop of medication per week and (or) the inability to accurately describe the medication regimen. Study personnel also assessed drop administration technique during application of eye drops by patients treating ophthalmologist-provided information, including measures of disease stability. Factors such as socioeconomic status, presence of caregiver, and number of medications with their effect on compliance were studied using chi-square statistics.
RESULTS: Among 151 patients interviewed, around 49% of patients reported problems in using glaucoma medications, with 16% of them reporting total non-compliance. 35% of patients demonstrated improper drop administration technique. Forgetfulness was cited as the main reason for being non-compliant and had a significant association with non-compliance (P = 0.00). Paying patients were more compliant as compared to subsidized patients (P = 0.05). Disease was more stable in compliant patients compared to non-compliant patients (P = 0.05). No other factor had significant association with compliance (P > 0.05).
CONCLUSIONS: Over 50% of the patients surveyed were non-compliant, and 35% demonstrated improper administration technique. Glaucoma patients should be educated on the importance of compliance and aids that minimize forgetfulness, and delivery systems facilitating the delivery of medications to the eye could be considered to enhance patient adherence.

Entities:  

Keywords:  Adherence; Glaucoma; Medication; North India

Year:  2018        PMID: 29988888      PMCID: PMC6033778          DOI: 10.1016/j.joco.2017.09.002

Source DB:  PubMed          Journal:  J Curr Ophthalmol        ISSN: 2452-2325


Introduction

Glaucoma contributes to 0.6 million disability-adjusted life years (DALYs) or 1.96% of the overall burden of diseases in India. A recent population-based study using modern techniques for detecting glaucoma suggested 11.2 million persons aged 40 years and older are affected due to glaucoma in India. Around 27.6 million persons were estimated to have some form of primary angle closure disease. Blindness among primary angle closure glaucoma (PACG) patients affects twice the number than those with primary open angle glaucoma (POAG). It is estimated that every eighth individual aged 40 years and over to be affected due to glaucoma or is at risk in the country. Glaucoma progression is associated with elevated intraocular pressure (IOP), and lowering IOP has been shown to inhibit the progression of glaucomatous optic nerve damage. Topical medications are an effective initial therapy in many patients, but studies have shown that it is often necessary to use multiple topical medications to achieve target IOP. However, a complicating factor to glaucoma treatment is that a large population of patients has been shown to have poor compliance. In a study in South India, 42% of the patients reported one or more problems in using their glaucoma medications, and around 6% of patients reporting less than 100% adherence to their medications during the week before. Various barriers to glaucoma treatment compliance exist, and these can be categorized into provider factors, situational/environmental factors, medication regimen factors, and patient factors. Glaucoma medication compliance can be determined using self-report, physician report, direct observation, electronic medication monitors, and pharmacy data. Self-reported compliance is probably the most commonly employed measure of compliance used in the clinical care of patients. The purpose of this study was to assess barriers to compliance to topical anti-glaucoma medications among glaucoma patients using self-reported compliance, and provide information for improving compliance in tertiary ophthalmic care settings.

Methods

A hospital based cross-sectional study was conducted among glaucoma patients aged 18 years and over at the Glaucoma Clinic at Dr. Shroff's Charity Eye Hospital, from June 2015–Jan 2016. Dr. Shroff's Charity Eye Hospital is a tertiary referral center providing general and subspecialty services and training. The study used a semi-structured questionnaire (See Annexure 1) to assess patient reported problems and adherence to glaucoma medications. However, the method of drop administration was observed by study personnel among patients or care-givers. The questions included demographic profile (socioeconomic status calculation with Kuppuswamy scale) and sections on barriers to compliance, patient views on glaucoma medications, number of medications, duration of treatment, and disease stability measured by visual field changes over time by treating glaucoma specialist's observation (who were masked to the nature of compliance of the patient). The study was approved by Institutional Ethics Committee of the hospital, and the patients who received treatment at the hospital participated in the survey. The survey questions were distributed by trained clinical staff to patients who were over 18 years of age presenting to the hospital out-patient department, diagnosed with glaucoma, and had been started on medications. Patients who were on medications for less than six months were excluded from the study. Verbal consent was taken from each of the 151 patients participating in the survey. The collected data was cleaned, edited, and coded in MS-Excel and analyzed using SPSS (Statistical Package for Social Scientist; version 20, IBM USA). Descriptive statistics in the form of frequencies and percentages were then calculated. The factors associated with non-compliance were explained between independent and dependent variable using chi-square statistics. Statistical significance was considered when the P-value stood at <0.05. In this study, ‘non-compliance’ stands for missing any of the drops in the last week (both partial and total non-compliance). ‘Partial compliance’ was defined as those missing at least one drop of medication per week and (or) the inability to accurately describe the medication regimen, and ‘total non-compliance’ was defined as not taking any prescribed glaucoma medication for one week. ‘Full compliance’ meant patient's adherence to regimen and was not missing any medication for the last one week. In addition to this, improper drop administration technique was also noted, whether the patient touched the bottle tip to the eye or if the drop missed the eye. In this study, mean defect in best eye on visual field was considered mild [better than −6 Decibel (dB)], moderate (−6 to −12 dB), and severe (worse than −12 dB). Doctor's perception of disease stability- A patient was defined as being stable if they had stable optic disc findings on subsequent disc photographs, no visual field progression, and IOP maintained in the target range. The disease was termed unstable/progressing if the patient had progression of disc findings (progressive cupping of optic disc, broadening or deepening of retinal nerve fiber layer defects or disc hemorrhage) with progression of glaucomatous field defects on visual field associated with IOP higher than the target pressure.

Results

A total of 151 patients were interviewed. The average age of the participants was 56.11 years, ranging from 18 years to 90 years. Most (66.23%) of the participants were over the age of 50 years, and two-thirds of them were males. Few (16.56%) of the participants were illiterate, though a majority (35.76%) were educated in the university. Most of the participants belonged to either middle or upper lower class as per Kuppuswamy scale. A significant majority (75.50%) had bilateral involvement of glaucoma in their eyes, and those affected with either eye had almost equal representation in the left or right eye. Most of the patients were on treatment duration of 5 years or less, and around 28% reported a history of glaucoma in the family (Table 1).
Table 1

Sociodemographic characteristics of participants.

Sociodemographic dataNumber (%)
Age
18–20 years2 (1.32)
21–30 years4 (2.65)
31–40 years12 (7.95)
41–50 years39 (25.83)
51–60 years34 (26.49)
61–70 years40 (26.49)
>70 years20 (13.25)
Sex
Male94 (62.5)
Female57 (37.75)
Education
Illiterate25 (16.56)
Middle-school24 (15.89)
High school (Class IX, X)26 (17.22)
Intermediate (Class XI, XII)22 (14.57)
University & above54 (35.76)
Socioeconomic class
Lower income24 (14.57)
Lower middle income44 (29.14)
Upper middle income79 (52.32)
Upper income6 (3.97)
Eyes treated
Bilateral114 (75.50)
RE19 (12.58)
LE18 (11.92)
Duration of treatment
<5 years103 (68.21)
>5–10 years33 (21.85)
>10–15 years8 (5.30)
>15 years7 (14.64)
Mean defect in best eye
Mild (better than −6 dB)91 (60.26)
Moderate (−6 to −12 dB)31 (20.53)
Severe (worse than −12 dB)29 (19.21)
Family members with glaucoma28 (18.54)
Patient category
General79 (52.31)
Paying72 (47.68)
Total151 (100%)
Sociodemographic characteristics of participants. Fifty-four patients (35.76%) were observed to conduct improper drop administration technique. Forty-nine patients touched the eye while instilling the drop, and 5 patients missed the eye. Around 49.33% of the interviewed patients mentioned missing at least some form of the prescribed medication in the past 1 week, with 16.67% of these patients having total non-compliance (Fig. 1). The most cited reason for non-compliance was forgetfulness, followed by outstation travel. Seven patients mentioned costs as one of the problems, while another 7 mentioned the unavailability of the prescribed drug as reasons for non-compliance (Table 2).
Fig. 1

Level of compliance to anti-glaucoma medications (n-151). The figure describes the patients' level of compliance to anti-glaucoma medications as total non-compliance, partial non-compliance, and full compliance (number-151).

Table 2

Main reasons given by participants for missing their doses in the week before.

ReasonPartial non-complianceTotal non-complianceTotal
Forgetfulness28533 (44.59%)
Outstation travel7310 (13.51%)
Others279 (12.16%)
Run out of drops404 (5.41%)
Cost of medicine257 (9.46%)
Unavailability of drugs437 (9.46%)
Discomfort022 (2.70%)
Laziness202 (2.70%)
TOTAL492574 (100%)
Level of compliance to anti-glaucoma medications (n-151). The figure describes the patients' level of compliance to anti-glaucoma medications as total non-compliance, partial non-compliance, and full compliance (number-151). Main reasons given by participants for missing their doses in the week before. The level of compliance was compared between various groups of patients. The results showed that only three parameters, i.e. doctors perception of stability of the disease (stable/unstable), cause of non-compliance, and patient category (paying/subsidized) were found to have a significant effect (P < 0.05) on non-compliance. The rest of the variables, such as age (P = 1.00), gender (P = 0.88), education (P = 0.10), socioeconomic status (P = 0.162), improper administration technique (P = 0.61), treatment period (P = 1.00), number of medications (P = 0.632), side-effect of medications (P = 0.54), scheduling difficulty (P = 0.66), presence of caregiver (P = 0.99), and visual defect severity (P = 1.00) did not show any significant effect on non-compliance (Table 3).
Table 3

Associated factors that determine non-compliance.

ANOVAdfSSMSFSignificance F

Regression1637.735099342.3584449.74336E+310
Residual1343.24356E-302.42E-32
Total15037.73509934

CoefficientsStandard errort StatP-valueLower 95%Upper 95%Lower 95.0%Upper 95.0%

Patient Category- P = Paying; G = Subsidized0.00.0−1.90.060.00.00.00.0
Age0.00.00.01.000.00.00.00.0
Sex0.00.00.10.880.00.00.00.0
Education0.00.0−1.70.100.00.00.00.0
Improper drop administration0.00.0−0.50.610.00.00.00.0
Method of improper technique (A. Missed the eye, B. Contaminated bottle tip, C-Both)0.00.00.40.660.00.00.00.0
Difficulty scheduling0.00.00.40.660.00.00.00.0
Cause of non-compliance1.00.00.40.001.01.01.01.0
Caregiver0.00.00.00.990.00.00.00.0
Side effects0.00.0−0.60.540.00.00.00.0
No. of administrations0.00.00.00.970.00.00.00.0
How do you feel about drops0.00.0−0.60.540.00.00.00.0
Treatment duration0.00.00.01.000.00.00.00.0
Family members with glaucoma0.00.0−1.00.340.00.00.00.0
Mean deviation of visual field0.00.00.01.000.00.00.00.0
Doctor's preception0.00.0−0.10.880.00.00.00.0

ANOVA: Analysis of variance, df: Degrees of freedom, SS: Sum of squares, MS: Mean sum of squares, F: F-statistic, t stat: t-statistic.

Associated factors that determine non-compliance. ANOVA: Analysis of variance, df: Degrees of freedom, SS: Sum of squares, MS: Mean sum of squares, F: F-statistic, t stat: t-statistic.

Discussion

Glaucoma is the leading cause of irreversible blindness in India. Poor glaucoma awareness8, 9 and under-utilization of ophthalmic services in the country adds to the existing glaucoma burden. In such circumstances, the need for increasing compliance of anti-glaucoma medications becomes imperative to manage this condition. This article reports using a sample of 151 patients through interviews and direct observation to explore the factors associated with treatment compliance to glaucoma medications in a tertiary eye care center in North India. The persistence with glaucoma medications have been found to be varying across several studies. In this study, around 49% of the interviewed patients reported either partial or total non-compliance with their glaucoma medications. However, in other developed and developing countries in Asia, the non-compliance rates have been found to be varied: Israel (29%), Hong Kong (63.4%), Taiwan (75.8%), Saudi Arabia (19.4%), and Pakistan (65.5%). The prevalence noted in the present study is in concordance with an earlier study done on glaucoma medication compliance in South India. The two previous studies on non-compliance conducted in North India reported non-compliance rates of 18% and 58%, respectively.16, 17 It is worrying to note that the earlier study in South India was done in 2009, and even though our study has been conducted seven years later, the percentage of non-compliance among patients with glaucoma remains high. This points to the fact that the knowledge of the ill-effects of medication non-compliance among glaucoma patients remains low, and there is need to ensure that patient education and community awareness on glaucoma needs to be focused in our country. Review of the studies from Asia show that difficulty opening the bottle, presence of a family member, older age,4, 14 and belonging to a rural area4, 13 influenced non-compliance rates. Among studies from India, including this present study, factors influencing non-compliance were dose forgetfulness16, 17 and cost. Being a developing nation with most of the patients without insurance coverage, we expected cost as a major cause of non-compliance. However, we noted forgetfulness to be the leading cause. Hence, proper counseling of patients regarding the need for compliance with the treatment should be emphasized by eye care providers. Studies18, 19, 20 have shown that electronic reminders could improve adherence to chronic conditions, such as glaucoma. Thus, some of the measures that could probably improve compliance are: making patients and relatives aware about the disease and its sequelae, development of support system to remind patient about drops, and use of electronic reminders such as short message service (SMS) and social media applications. Although a greater number of patients belonged to middle and lower socioeconomic status as per Kuppuswamy scale, we noted an equal number of patients under paying and subsidized category clinics. Thus, the patients with lower socioeconomic status also opted for paid clinics in our study. There is a possibility that these categories of patients are more concerned about the disease and its implications. This, in turn, may explain higher compliance among paying patients. The patients who were compliant were noted to be stable in terms of glaucoma progression by the treating ophthalmologist, as compared to the non-compliant patients. Non-compliance to drops leads to glaucoma progression due to inadequate IOP control and subsequent optic nerve damage. Konstas et al. have reported progression of visual field and disc cupping in non-compliant patients. However, in an evidence based review by Olthoff et al., no strong evidence supporting a relation between non-compliance and progression of visual field (VF) loss was found. 36 percent of our patients were noted to conduct improper drop administration technique. Poor aim can result in under-treatment and disease progression. On the contrary, repeated attempts can lead to excess medication administration and over-treatment, with higher medication costs and increased risk of side effects. Contact of the tip of the eye drop container to the eye or skin has consequences that range from contamination24, 25, 26 to trauma. A recent review article concludes that the aids named “Eyot” and “inverted, funnel-shaped guide” have positive objective and/or subjective study outcomes on eye drop instillation. Elderly patients and those with musculoskeletal comorbidities may benefit most from instillation aids. We also recommend eye drop administration aids to minimize improper drop administration technique. As a follow-up measure in the hospital, to take care of the problem of non-compliance, we have incorporated counselors to explain glaucoma and the need for compliance to anti-glaucoma medications to patients. The importance of the caregiver is also emphasized to the patients. We also recommended developing patient reminder systems to increase compliance to the hospital authorities. The study has a few limitations. As described in several studies, the method of using self-report through use of questionnaires could result in an overestimation of the results on compliance. Second, the study was conducted among patients who reported to a clinic for glaucoma treatment. Future research should look at the barriers of medication compliance using a community-based study on patients who have reported to such clinics and later have not returned for follow-up examinations. Lastly, this study was conducted at a single glaucoma clinic in North India; hence the generalizability of the study is limited. Notwithstanding these limitations, our study has several strengths. The measures of non-compliance through improper administration technique were observed by study personnel of the patients/caregivers putting the eye drops. Around 43% of the study participants reported being from a lower socioeconomic background, which reflects the fact that the hospital is a charitable health facility with tertiary care facilities catering to lower, middle, and upper income category of the Indian population at large. Trained clinical staff administered the questionnaire used on the patients during the interviews. Our study found a substantial level of non-compliance among patients reporting to a glaucoma clinic in North India. Among the 49% of patients who reported less than 100% adherence to their glaucoma medications in the previous week, around 16% reported total non-compliance. There is need for doctors and glaucoma clinics to pay more attention to the issue of medication non-compliance among patients reporting to health facilities. A support system to remind patients about glaucoma medications is required.
  22 in total

1.  Microbial contamination of in-use ocular medications.

Authors:  O D Schein; P L Hibberd; T Starck; A S Baker; K R Kenyon
Journal:  Arch Ophthalmol       Date:  1992-01

Review 2.  Aids for eye drop administration.

Authors:  Isaiah Davies; Andrew M Williams; Kelly W Muir
Journal:  Surv Ophthalmol       Date:  2016-12-21       Impact factor: 6.048

3.  The effect of a medication alarm device on patient compliance with topical pilocarpine.

Authors:  S F Laster; J L Martin; J B Fleming
Journal:  J Am Optom Assoc       Date:  1996-11

4.  Timolol eyedrop-induced severe bronchospasm.

Authors:  S Ostergaard Laursen; P Bjerrum
Journal:  Acta Med Scand       Date:  1982

5.  Compliance of Glaucoma Patients to Ocular Hypotensive Medications Among the Saudi Population.

Authors:  Essam A Osman; Bader Ahmed Mousa Alqarni; Sara Salem Humaid AlHasani; Shatha Saleh Suliman Al Harbi; Priscilla Wairimu Gikandi; Ahmed Mousa
Journal:  J Ocul Pharmacol Ther       Date:  2015-11-24       Impact factor: 2.671

6.  Compliance barriers in glaucoma: a systematic classification.

Authors:  James C Tsai; Cori A McClure; Sarah E Ramos; David G Schlundt; James W Pichert
Journal:  J Glaucoma       Date:  2003-10       Impact factor: 2.503

7.  Microbial contamination of glaucoma eyedrops used by patients compared with ocular medications used in the hospital.

Authors:  Barbara Teuchner; Julia Wagner; Nikolaos E Bechrakis; Dorothea Orth-Höller; Markus Nagl
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

8.  Factors associated with adherence to glaucoma pharmacotherapy in the primary care setting.

Authors:  Orit Cohen Castel; Lital Keinan-Boker; Orna Geyer; Uzi Milman; Khaled Karkabi
Journal:  Fam Pract       Date:  2014-06-12       Impact factor: 2.267

9.  Determinants of glaucoma awareness and knowledge in urban Chennai.

Authors:  Ramesh Ve Sathyamangalam; Pradeep G Paul; Ronnie George; Mani Baskaran; Arvind Hemamalini; Raj V Madan; J Augustian; Raju Prema; Vijaya Lingam
Journal:  Indian J Ophthalmol       Date:  2009 Sep-Oct       Impact factor: 1.848

10.  Patient-reported barriers to glaucoma medication access, use, and adherence in southern India.

Authors:  Betsy L Sleath; R Krishnadas; Minhee Cho; Alan L Robin; Rakhi Mehta; David Covert; Gail Tudor
Journal:  Indian J Ophthalmol       Date:  2009 Jan-Feb       Impact factor: 1.848

View more
  10 in total

1.  ISOPT Clinical Hot Topic Panel Discussion on Ocular Drug Delivery.

Authors:  Uday B Kompella; Abraham Domb; Arto Urtti; Ashwath Jayagopal; Clive G Wilson; Diane Tang-Liu
Journal:  J Ocul Pharmacol Ther       Date:  2019-06-28       Impact factor: 2.671

2.  Evaluation of Compliance Issues to Anti-glaucoma Medications Before and After a Structured Interventional Program.

Authors:  Irshad A Subhan; Rawan Alosaimy; Nouf T Alotaibi; Bayan Mirza; Ghufran Mirza; Orjwan Bantan
Journal:  Cureus       Date:  2022-06-14

Review 3.  Adherence to Therapy in Glaucoma Treatment-A Review.

Authors:  Alexandra-Cătălina Zaharia; Otilia-Maria Dumitrescu; Mădălina Radu; Roxana-Elena Rogoz
Journal:  J Pers Med       Date:  2022-03-22

4.  Level of Glaucoma Drug Adherence and Its Associated Factors Among Adult Glaucoma Patients Attending Felege Hiwot Specialized Hospital, Bahir Dar City, Northwest Ethiopia.

Authors:  Abel Sinshaw Assem; Sofonias Addis Fekadu; Amsal Ambaw Yigzaw; Zelalem Mehari Nigussie; Anemaw Asrat Achamyeleh
Journal:  Clin Optom (Auckl)       Date:  2020-10-27

5.  Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility.

Authors:  Gavin W Roddy; Uttio Roy Chowdhury; Kjersten J Anderson; Tommy A Rinkoski; Cheryl R Hann; Vince A Chiodo; W Clay Smith; Michael P Fautsch
Journal:  PLoS One       Date:  2022-05-31       Impact factor: 3.752

6.  Comparison of safety and efficacy of drug delivery by topical application versus drug-eluting contact lens in cataract surgery.

Authors:  Mandal Debasish; Bandyopadhyay Debabrata
Journal:  Indian J Ophthalmol       Date:  2021-02       Impact factor: 1.848

Review 7.  Ophthalmic Nanoemulsions: From Composition to Technological Processes and Quality Control.

Authors:  Agnieszka Gawin-Mikołajewicz; Karol P Nartowski; Aleksandra J Dyba; Anna M Gołkowska; Katarzyna Malec; Bożena Karolewicz
Journal:  Mol Pharm       Date:  2021-09-17       Impact factor: 4.939

8.  Initial experience with phacoemulsification and goniotomy using the Kahook dual blade in advanced open-angle glaucoma: Six-month outcomes in Indian eyes.

Authors:  Rashmi Krishnamurthy; Sirisha Senthil; Nikhil Choudhari
Journal:  Indian J Ophthalmol       Date:  2021-09       Impact factor: 1.848

Review 9.  Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma.

Authors:  Uday B Kompella; Rachel R Hartman; Madhoosudan A Patil
Journal:  Prog Retin Eye Res       Date:  2020-09-04       Impact factor: 21.198

10.  Incidence of ocular and systemic diseases affecting visual function among state bus drivers.

Authors:  Piyush Kohli; Naresh Babu; Chitaranjan Mishra; Sourav Damodaran; S Bhavani; Mahesh Kumar; Kim Ramasamy
Journal:  Indian J Ophthalmol       Date:  2021-10       Impact factor: 1.848

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.